SavedAdd your journal

Journals / Journal of Clinical Research in Pediatric Endocrinology / 2016 / Cilt: 8 - Sayı: 1

Growth Hormone Deficiency in a Child with Neurofibromatosis-Noonan Syndrome

DOĞUŞ VURALLI KARAOĞLAN
ELMAS NAZLI GÖNÇ
Dominique VİDAUD
ZEYNEP ALEV ÖZÖN
AYFER ALİKAŞİFOĞLU
Nurgün KANDEMİR
Pages
96–100
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with NFNS who show poor growth should be evaluated for GHD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neurofibromatosis-Noonan syndrome (NFNS) is a distinct entity which shows the features of both NF1 (neurofibromatosis 1) and Noonan syndrome (NS).
📊
Key Findings & Data:While growth hormone deficiency (GHD) has been relatively frequently identified in NF1 and NS patients, there is limited experience in NFNS cases.
💡
Conclusion & Impact:Patients with NFNS who show poor growth should be evaluated for GHD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neurofibromatosis-Noonan syndrome (NFNS) is a distinct entity which shows the features of both NF1 (neurofibromatosis 1) and Noonan syndrome (NS). While growth hormone deficiency (GHD) has been relatively frequently identified in NF1 and NS patients, there is limited experience in NFNS cases. The literature includes only one case report of a NFNS patient having GHD and that report primarily focuses on the dermatological lesions that accompany the syndrome and not on growth hormone (GH) treatment. Here, we present a 13-year-old girl who had clinical features of NFNS with a mutation in the NF1 gene. The case is the first NFNS patient reported in the literature who was diagnosed to have GHD and who received GH treatment until reaching final height. The findings in this patient show that short stature is a feature of NFNS and can be caused by GHD. Patients with NFNS who show poor growth should be evaluated for GHD.

🔖

Cite This Article

KARAOĞLAN, D. V., GÖNÇ, E. N., VİDAUD, D., ÖZÖN, Z. A., ALİKAŞİFOĞLU, A., KANDEMİR, N. (2016). Growth Hormone Deficiency in a Child with Neurofibromatosis-Noonan Syndrome. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 8 - Sayı: 1, 96–100. https://ajindex.com/articles/216344

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Allanson JE, Hall JG, Van Allen MI. Noonan phenotype associated with neurofibromatosis. Am J Med Genet 1985;21:457-462
  2. Opitz JM, Weaver DD. The neurofibromatosis-Noonan syndrome. Am J Med Genet 1985;21:477-490
  3. Kaplan P, Rosenblatt B. A distinctive facial appearance in neurofibromatosis von Recklinghausen. Am J Med Genet 1985;21:463-470
  4. Mendez HM. The neurofibromatosis-Noonan syndrome. Am J Med Genet 1985;21:471-476
  5. Saul RA. Noonan syndrome in a patient with hyperplasia of the myenteric plexuses and neurofibromatosis. Am J Med Genet 1985;21:491-492
  6. Meinecke P. Evidence that the "neurofibromatosis-Noonan syndrome" is a variant of von Recklinghausen neurofibromatosis. Am J Med Genet 1987;26:741-745
  7. Quattrin T, McPherson E, Putnam T. Vertical transmission of the neurofibromatosis/Noonan syndrome. Am J Med Genet 1987;26:645-649
  8. Shuper A, Mukamel M, Mimouni M, Steinherz R. Noonan's syndrome and neurofibromatosis. Arch Dis Child 1987;62:196- 198
  9. Abuelo DN, Meryash DL. Neurofibromatosis with fully expressed Noonan syndrome. Am J Med Genet 1988;29:937-941
  10. Stern HJ, Saal HM, Lee JS, Fain PR, Goldgar DE, Rosenbaum KN, Barker DF. Clinical variability of type 1 neurofibromatosis: is there a neurofibromatosis-Noonan syndrome? J Med Genet 1992;29:184-187
  11. Colley A, Donnai D, Evans DG. Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clin Genet 1996;49:59-64
  12. Bertola DR, Pereira AC, Passetti F, de Oliveira PS, Messiaen L, Gelb BD, Kim CA, Krieger JE. Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. Am J Med Genet A 2005;136:242-245
  13. Thiel C, Wilken M, Zenker M, Sticht H, Fahsold R, GusekSchneider GC, Rauch A. Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome. Am J Med Genet A 2009;149:1263-1267
  14. Noonan JA, Kappelgaard AM. The Efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence. Horm Res Paediatr 2015;83:157-166. Epub 2014 Dec 10 15. Vassilopoulou-Sellin R, Klein MJ, Slopis JK. Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions. Pediatr Neurol 2000;22:355-358
  15. Carmi D, Shohat M, Metzker A, Dickerman Z: Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics 1999;103:1257-1262
  16. Kirk JM, Betts PR, Butler GE,